Bellicum Pharmaceuticals, Inc. (BLCM)
| Previous close | 0.2240 |
| Open | 0.2408 |
| Bid | 0.0000 x 800 |
| Ask | 0.0000 x 800 |
| Day's range | 0.2408 - 0.2800 |
| 52-week range | 0.0600 - 1.5000 |
| Volume | |
| Avg. volume | 17,585 |
| Market cap | 2.721M |
| Beta (5Y monthly) | 1.36 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Bellicum Discontinues Phase 1/2 Trials and Initiates Evaluation of Strategic Alternatives
HOUSTON, March 14, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (Nasdaq: BLCM), today announced its decision to discontinue its ongoing Phase 1/2 clinical trials evaluating the safety and preliminary efficacy of its GoCAR-T cell product candidates in combination with rimiducid in heavily pre-treated cancer patients. The trials for BPX-601 and BPX-603 are being discontinued following the Company’s assessment of the risk/benefit profile of BPX-601 in combination with rimiducid. The most
- GlobeNewswire
Bellicum Presents Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO GU Cancers Symposium
Biochemical and radiographic responses reported in first two cohorts of dose escalation in heavily pre-treated metastatic castration-resistant prostate cancer (mCRPC) patients PSA50 or greater responses in 50% of patients Responses observed in patients with visceral, nodal and bone involvement HOUSTON, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today will present early Phase 1 re
- GlobeNewswire
CORRECTION -- Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
HOUSTON, Jan. 31, 2023 (GLOBE NEWSWIRE) -- In a release issued earlier today by Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), please note that the total number of stock options should be 20,000, not 45,000, as previously stated. The corrected release follows: Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced equity inducement grants to 1 new employee consisting of an aggregate of 20,000 stock options. Th
